Lupin inks licensing pact with SteinCares for biosimilar

27 May 2025 , 10:29 AM

Lupin Limited on Monday announced that it has entered into a licensing and supply pact with SteinCares. The agreement is for biosimilar Ranibizumab in Latin America, excluding Mexico and Argentina.

As per the terms of agreement, Lupin plans to manufacture the biosimilar, while SteinCares will look after regulatory filings, commercialisation across the regions, and registrations.

As per the company’s filing with the bourses, Ranibizumab is used to treat several retinal disorders. This also includes age-related macular degeneration and diabetic macular edema.

Lupin informed the bourses and shareholders that the objective of this collaboration is to widen its access to advanced retinal therapies across the LATAM region. 

StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin America. 

Lupin is a global pharmaceutical company set up in 1968 by Desh Bandhu Gupta. The company has its headquarters in Mumbai, India. The business has its specialization in generic formulations, biosimilars, specialty drugs, and active pharmaceutical ingredients (APIs). The company marks a robust presence in Europe, India, Japan, and the United States.

The business posted a sharp increase of 112.40% in its net profit for the quarter ended March 2025. The business said that its consolidated net profit of ₹782.40 Crore in the period under review. In the previous corresponding period, the business posted a net profit of ₹368.20 Crore.

For feedback and suggestions, write to us at [e-mail]